Table S3. Survival analysis of immunohistochemical staining.
| Marker | OS | DFS | PFS | MFS |
|---|---|---|---|---|
| CD117 | P=0.17 | P=0.29 | P=0.42 | P=0.67 |
| CD5 | HR 1.016; CI: 0.983–1.050; P=0.35 | HR 1.005; CI: 0.985–1.026; P=0.596 | HR 1.012; CI: 0.975–1.050; P=0.54 | HR 1.002; CI: 0.987–1.016; P=0.83 |
| p63 | HR 0.988; CI: 0.961–1.016; P=0.41 | HR 0.990; CI: 0.965–1.017; P=0.47 | HR 1.006; CI: 0.962–1.051; P=0.81 | HR 0.995; CI: 0.975–1.015; P=0.60 |
| p40 | HR 0.997; CI: 0.986–1.008; P=0.58 | HR 0.992; CI: 0.979–1.005; P=0.23 | HR 1.002; CI: 0.988–1.017; P=0.76 | HR 0.996; CI: 0.998–1.004;P=0.36 |
| p21 nucleus | HR 1.029; CI: 0.990–1.080; P=0.15 | HR 1.025; CI: 0.975–1.078; P=0.34 | HR 1.127; CI: 0.962–1.319; P=0.14 | HR 1.009; CI: 1.000–1.018; P=0.053 |
| p21 cytoplasm | HR 1.044; CI: 1.008–1.081; P=0.016* | HR 1.041; CI: 0.989–1.096; P=0.12 | HR 1.047; CI: 1.004–0.093; P=0.034* | HR 1.017; CI: 1.005–1.029; P=0.005* |
| p27 nucleus | HR 1.022; CI: 0.998–1.046; P=0.078 | HR 1.013; CI: 0.992–1.035; P=0.23 | HR 1.018; CI: 0.996–1.042; P=0.11 | HR 1.003; CI: 0.993–1.013; P=0.62 |
| p27 cytoplasm | HR 1.014; CI: 0.993–1.036; P=0.20 | HR 1.008; CI: 0.985–1.032; P=0.49 | HR 1.024; CI: 0.998–1.052; P=0.078 | HR 1.003; CI: 0.991–1.015; P=0.59 |
| p53 | HR 1.016; CI: 0.998–1.034; P=0.083 | HR 1.008; CI: 0.991–1.024; P=0.38 | HR 0.999; CI: 0.979–1.019; P=0.92 | HR 1.004; CI: 0.993–1.015; P=0.45 |
| p21 low, p27 low, p53 high | – | – | – | P=0.029* |
| p21 low, p53 high | P=0.68 | P=0.52 | P=0.20 | P=0.18 |
| Bcl-2 | HR 1.007; CI: 0.997–1.018; P=0.18 | HR 1.004; CI: 0.996–1.012; P=0.36 | HR 1.003; CI: 0.993–1.012; P=0.60 | HR 1.001; CI: 0.996–1.006; P=0.64 |
| Ki-67 | HR 1.037; CI: 0.976–1.101; P=0.24 | HR 1.006; CI: 0.947–1.068; P=0.85 | HR 1.081; CI: 0.995–1.174; P=0.064 | HR 1.005; CI: 0.967–1.046; P=0.79 |
| Podoplanin | P=0.41 | P=0.23 | – | P=0.38 |
| Synaptophysin | P=0.24 | P=0.10 | P=0.85 | P=0.91 |
| PTEN | HR 0.985; CI: 0.955–1.016; P=0.34 | HR 1.004; CI: 0.989–1.020; P=0.60 | HR 1.005; CI: 0.963–1.049; P=0.80 | HR 1.000; CI: 0.988–1.012; P=0.99 |
| Pax8 nucleus | HR 1.0; CI: 0.984–1.016; P=0.98 | HR 1.008; CI: 0.992–1.024; P=0.34 | HR 1.004; CI: 0.988–1.020; P=0.67 | HR 1.002; CI: 0.994–1.010; P=0.58 |
| Pax8 cytoplasm | HR 1.008; CI: 0.987–1.030; P=0.45 | HR 1.010; CI: 0.992–1.029; P=0.28 | HR 0.995; CI: 0.958–1.034; P=0.80 | HR 0.999; CI: 0.987–1.012; P=0.90 |
*, significant P value (P<0.05) and 95% confidence interval. OS, overall survival; DFS, disease-free survival; PFS, progression-free survival; MFS, metastasis-free survival; HR, hazard ratio; CI, 95% confidence interval; P, P value.